Table 4. Estimates of medical, non-medical, and indirect costs of oral cancer presented in the methods of studies from 2001 to 2020.
Study | Direct costs | Indirect cost | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Medical costs | Non-medical costs | Absenteeism | Early Death | |||||||
Surgery | Chemotherapy | Radiotherapy | Follow up | Medications | Exams | |||||
Longitudinal studies | ||||||||||
1. Kim, 2011 [23] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
2. Polesel, 2019 [26] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
3. Jacobson, 2012 [24] | ✓ | ✓ | ✓ | ✓ | ✓ | |||||
4. Pollaers, 2019 [25] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
5. Huang, 2020 [27] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
Cross-sectional and case control studies | ||||||||||
6. Rezapour, 2018 [29] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
7. van Aghtoven, 2001 [35] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
8. Fisher, 2018 [36] | ✓ | ✓ | ✓ | |||||||
9. Nijdam, 2005 [32] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
10. Amarasinghe, 2019 [18] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||
11. Goyal, 2014 [33] | ✓ | ✓ | ✓ | ✓ | ||||||
12. Zavras, 2002 [37] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
13. van der Linden, 2016 [38] | ✓ | ✓ | ✓ | ✓ | ✓ | |||||
14. Epstein, 2008 [34] | ✓ | ✓ | ✓ | ✓ | ✓ | |||||
15. Lafuma, 2019 [30] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
16. Patterson, 2020 [31] | ✓ | |||||||||
17. Han, 2010 [39] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||
18. Enomoto, 2015 [40] | ✓ | |||||||||
19. Lairson, 2017 [41] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
20. Kim, 2020 [19] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
Cross-sectional studies based on information system data | ||||||||||
21. Vatanasapt, 2012 [20] | ✓ | ✓ | ✓ | |||||||
22. Klussmann, 2013 [28] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
23. Keeping, 2018 [21] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||
24. Milani, 2021 [22] | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |